Focus on Breakthrough Pathways, Promote Industry Upgrading: RNAi Salon (Beijing Station) Successfully Concluded
July 29, Beijing / Sci-Tech Daily/ -- On July, , Biotechnology company GeneOrum successfully hosted "RNAi Salon (Beijing Station)", a conference that delved into the development trends, delivery challenges, CMC compliance, patent strategies, and future commercialization pathways for small nucleic acid drugs. The event attracted many professionals from research institutions, biopharmaceutical companies, and investment organizations.
The salon set up themed reports and roundtable discussion sessions, focusing on topics such as the structure modification of nucleic acid drugs, delivery systems, adaptive selection, non-hepatocyte targeting strategies, clinical landing, and intellectual property rights.
Technical Depth: Exploring from Structure Modification to Delivery Systems
Dr. Wang Haisheng delivered a keynote report on the types of small nucleic acid drugs, their mechanisms of action, representative products, and the development of delivery systems, pointing out that chemical modification and organ targeting are key variables driving the success of nucleic acid drugs.
Professor Chen Lianxun then presented original research results from his team on non-hepatocyte targeting delivery, showcasing ring-shaped condensation, structure control, brain-targeted delivery technologies. Through simulation of high-salinity marine environments and construction of ring-shaped nucleic acid structures, the stability and penetration efficiency of nucleic acids were significantly enhanced, with good prospects for application in blood vessel regeneration and neurosystem disease models.
Professor Zhang Lijing focused on the selection and delivery strategies of nucleic acid drugs, sharing methods for affinity screening using fluorescent signal destruction mechanisms. He also pointed out that intracellular delivery remains a key bottleneck limiting the widespread application of nucleic acid drugs, looking forward to platform tools accelerating functional verification pathways.
Interchange of Opinions: Focusing on Realistic Challenges and Diversified Strategies
The roundtable discussion focused on "Breakthrough Pathways for Domestic Small Nucleic Acid Drug Delivery Technologies and Industry Challenges". Experts attending the event agreed that there is still a significant need to improve in core modification technologies, patent protection, and diversified strategies.
The common challenges faced by the industry include: technical bottlenecks in delivery systems, CMC consistency construction difficulties, doctor-patient cognition insufficiency, high raw material costs, and intense homogeneous competition. In the future, focus should be on unsatisfied clinical needs and more forward-looking directions, such as rare diseases and neurodegenerative diseases.
GeneOrum's Position: As a Connector, Supporter, and Promoter
As the host of this conference, GeneOrum hopes to build a communication bridge between upstream and downstream industries through this salon, gathering technical opinions and promoting the construction of a collaborative ecosystem.
GeneOrum is currently actively laying out small nucleic acid synthesis and modification service platforms, focusing on high-purity synthesis, diversified modification development, clinical-grade raw material supply system construction, and continuous improvement in its professional abilities in the fields of nucleic acid drug materials and technologies.
In the future, GeneOrum will continue to collaborate with research institutions and pharmaceutical companies, jointly promoting the efficient and safe industrial transformation and breakthroughs of small nucleic acid drugs in China.